通过RET免疫组化过表达识别TMEM127缺陷型嗜铬细胞瘤/副神经节瘤
本研究在104例临床和遗传学多样的PPGL石蜡切片中行RET免疫组化,发现TMEM127变异驱动肿瘤的RET表达评分最高(151.8±62),显著高于RET致病突变(69.9±96.8)及未明确基因型肿瘤(40.8±69),提示RET膜表达可作为TMEM127功能缺失变异的生物标志物。
要点
- TMEM127变异型PPGL的RET免疫组化评分最高,且以膜染色为主。
- RET膜免疫反应可区分TMEM127可能致病与非破坏性变异。
- 若独立队列验证,RET免疫组化或有助于评估TMEM127 VUS的功能意义。
核心结论
- RET膜表达增加是PPGL中TMEM127功能缺失变异有前景的生物标志物。
研究设计与样本
- 对104例临床和遗传学多样的PPGL石蜡切片行RET免疫组化,手工计算膜、胞质及总H-S,并对胞质和总H-S进行数字化评分。
主要发现
- TMEM127变异驱动肿瘤RET评分最高(151.8±62),以膜染色为主。
- TMEM127变异肿瘤评分高于RET致病突变肿瘤(69.9±96.8,校正p=0.03)。
- TMEM127变异肿瘤评分高于未明确基因型肿瘤(40.8±69,校正p=0.0001)。
- 数字化评分与手工H-S高度相关(胞质0.74,总0.80)。
- RET膜免疫反应可区分TMEM127可能致病与非破坏性变异。
临床怎么用
- RET免疫组化有望辅助识别携带TMEM127功能缺失变异的PPGL,尤其是VUS病例。
- 需在独立队列验证后方可用于临床评估TMEM127 VUS的功能意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are rare, genetically diverse tumors originating from the adrenal medulla or extra-adrenal paraganglia, respectively. Knowledge of the pathogenic status of genetic variants, especially in the 35-40% of patients with germline changes, impacts management and family surveillance. However, interpreting variants of uncertain significance (VUS) remains challenging, particularly for poorly characterized genes such as TMEM127, and often requires additional testing. We recently reported that TMEM127 loss promotes RET accumulation by reducing its degradation. OBJECTIVE: We evaluated RET expression by immunohistochemistry (IHC) as a potential aid to highlight TMEM127 dysfunction in PPGLs carrying TMEM127 germline variants. METHODS: We performed RET IHC in 104 formalin-fixed and paraffin-embedded (FFPE) sections of clinically and genetically diverse PPGLs and generated histochemical scores (H-S) manually for membrane (MH-S), cytoplasm (CH-S) and their sum (total TH-S), and digitally for CH-S and TH-S. RESULTS: Tumors driven by TMEM127 variants carried the highest RET expression scores (151.8 ± 62), predominantly MH-S, when compared with other PPGL genotypes, including RET pathogenic disruptions (69.9 ± 96.8, adjusted p = 0.03) or tumors of undefined genotype (40.8 ± 69, adjusted p = 0.0001). Digital scoring showed high correlation with manual H-S (0.74 and 0.80 for C-HS and TH-S, respectively). RET membrane immunoreactivity also distinguished PPGLs carrying likely damaging from non-disrupting TMEM127 variants. CONCLUSIONS: These findings point to increased RET membrane expression as a promising biomarker for loss-of-function TMEM127 variants in PPGLs. If validated in independent cohorts, RET IHC could be an effective tool for assessing the functional implications of PPGLs from patients carrying TMEM127 VUS.
引用
- Estrada-Zuniga CM, Liang R, Landry B, et al. Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry. J Clin Endocrinol Metab. 2026. PMID: 42464758. doi:10.1210/clinem/dgag288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。